VRTX240927C470000
- 1.60
- +0.10+6.67%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Vertex Pharmaceuticals (VRTX) Gets a Hold From RBC Capital
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals: A Cautious Hold Amidst Mixed Financial Signals and Pipeline Uncertainty
Redburn Atlantic Adjusts Price Target on Vertex Pharmaceuticals to $560 From $545
Vertex Pharmaceuticals Price Target Raised to $600.00/Share From $500.00 by HC Wainwright & Co.
Vertex Downgraded at Barclays Due to Valuation
JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $510
Oppenheimer Initiates Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $550
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $550
Vertex Pharmaceuticals (VRTX) Gets a Buy From Truist Financial
Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays
Barclays Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $509 From $472
Barclays Downgrades Vertex Pharmaceuticals(VRTX.US) to Hold Rating, Raises Target Price to $509
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)
Analyst Issues Sell Rating on Vertex Pharmaceuticals Amid Maturing CF Products and Overvalued Pain Franchise
Buy Rating on Vertex Pharmaceuticals: Uncovering the Market Potential of Novel Pain Treatments
Buy Rating Reaffirmed for Vertex Pharmaceuticals Amid Strong Performance and Promising Pipeline